SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 3.50 million shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2025-11-06
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 3.50M shares, a 2487.98% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-06-30 was 317.32K shares, a 477.94% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-03-31 was 1.50M shares, a 28.93% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-09-30 was 135.09K shares, a 390.55% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month as first filed |
|---|---|---|---|---|
| 2025-09-30 | 3.50M shares 10-Q · filed 2025-11-06 | 3.81M shares derived: sum of 2 quarters · filed 2025-11-06 | 5.19M shares 10-Q · filed 2025-11-06 | |
| 2025-06-30 | 317.32K shares 10-Q · filed 2025-08-06 | 1.82M shares 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | 1.50M shares 10-Q · filed 2025-05-06 | |||
| 2024-09-30 | 135.09K shares 10-Q · filed 2025-11-06 | 190.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.25M shares 10-Q · filed 2025-11-06 | 1.35M shares 10-Q · filed 2024-11-06 |
| 2024-06-30 | 54.91K shares 10-Q · filed 2025-08-06 | 1.22M shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 1.16M shares 10-Q · filed 2025-05-06 | |||
| 2023-09-30 | 27.54K shares 10-Q · filed 2024-11-06 | 61.29K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.14M shares 10-Q · filed 2024-11-06 | |
| 2023-06-30 | 33.75K shares 10-Q · filed 2024-08-07 | 1.11M shares 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 1.08M shares 10-Q · filed 2024-05-01 | |||
| 2022-09-30 | 65.66K shares 10-Q · filed 2023-11-01 | 212.73K shares derived: sum of 2 quarters · filed 2023-11-01 | 925.17K shares 10-Q · filed 2023-11-01 | |
| 2022-06-30 | 147.07K shares 10-Q · filed 2023-08-02 | 859.51K shares 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | 712.43K shares 10-Q · filed 2023-05-02 | |||
| 2021-09-30 | 47.59K shares 10-Q · filed 2022-11-02 | 84.83K shares derived: sum of 2 quarters · filed 2022-11-02 | 774.20K shares 10-Q · filed 2022-11-02 | |
| 2021-06-30 | 37.24K shares 10-Q · filed 2022-08-02 | 726.61K shares 10-Q · filed 2022-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |